Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure

Abstract

Background Extracorporeal membrane oxygenation (ECMO) support in acute respiratory failure may be lifesaving, but bleeding and thromboembolic complications are common. The optimal anticoagulation strategy balancing these factors remains to be determined. This retrospective study compared two institutional anticoagulation management strategies focussing on oxygenator changes and both bleeding and thromboembolic events. Methods We conducted a retrospective observational cohort study between 04/2015 and 02/2020 in two ECMO referral centres in Germany in patients receiving veno-venous (VV)-ECMO support for acute respiratory failure for > 24 h. One centre routinely applied low-dose heparinization aiming for a partial thromboplastin time (PTT) of 35–40 s and the other routinely used a high-dose therapeutic heparinization strategy aiming for an activated clotting time (ACT) of 140–180 s. We assessed number of and time to ECMO oxygenator changes, 15-day freedom from oxygenator change, major bleeding events, thromboembolic events, 30-day ICU mortality, activated clotting time and partial thromboplastin time and administration of blood products. Primary outcome was the occurrence of oxygenator changes depending on heparinization strategy; main secondary outcomes were the occurrence of severe bleeding events and occurrence of thromboembolic events. The transfusion strategy was more liberal in the low-dose centre. Results Of 375 screened patients receiving VV-ECMO support, 218 were included in the analysis (117 high-dose group; 101 low-dose group). Disease severity measured by SAPS II score was 46 (IQR 36–57) versus 47 (IQR 37–55) and ECMO runtime was 8 (IQR 5–12) versus 11 (IQR 7–17) days (P = 0.003). There were 14 oxygenator changes in the high-dose group versus 48 in the low-dose group. Freedom from oxygenator change at 15 days was 73% versus 55% (adjusted HR 3.34 [95% confidence interval 1.2–9.4]; P = 0.023). Severe bleeding events occurred in 23 (19.7%) versus 14 (13.9%) patients (P = 0.256) and thromboembolic events occurred in 8 (6.8%) versus 19 (19%) patients (P = 0.007). Mortality at 30 days was 33.3% versus 30.7% (P = 0.11). Conclusions In this retrospective study, ECMO management with high-dose heparinization was associated with lower rates of oxygenator changes and thromboembolic events when compared to a low-dose heparinization strategy. Prospective, randomized trials are needed to determine the optimal anticoagulation strategy in patients receiving ECMO support.

Contraindications to the Initiation of Veno-Venous ECMO for Severe Acute Respiratory Failure in Adults: A Systematic Review and Practical Approach Based on the Current Literature

“…The same results were presented in a systematic review [ 158 ]. However, in an even more recent retrospective analysis, it was found that “ECMO management with high-dose heparinization was associated with lower rates of oxygenator changes and thromboembolic events when compared to a low-dose heparinization strategy” [ 159 ].…”

Massive hemoptysis managed by prolonged anticoagulation-free veno-venous extracorporeal membrane oxygenation with which thoracic surgeries were accompanied: a case report

“…Although the PMEA-coated system we employed is indicated to reduce circuit-related adverse effects such as inflammatory responses and thrombo-coagulopathies, these findings were obtained only by either in vitro studies or short-term uses. In addition, only a few case-based studies reported feasibility of long-term VV-ECMO with low-dose anticoagulant uses [ 9 , 10 ]. Therefore, we needed to pay considerable attention to coagulation status in the circulation.…”

It takes two to bleed: anticoagulation intensity and the host’s vascular susceptibility

“…Our group demonstrated that different heparin monitoring and dosing strategies result in ample differences in BTE occurrence with mean heparin doses differing by 60% between experienced centers and, quite unsurprisingly, bleeding occurring far more often with higher heparin doses, while thrombotic events peak with lower doses [2].…”

“…Author details 1 Hannover Medical School, Department of Respiratory Medicine and Biomedical Research in End-Stage and Obstructive Lung Disease Hannover, German Center for Lung Research, Hannover, Germany. 2 Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland. 3 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.…”